[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# $gpcr

Structure Therapeutics' oral obesity drug shows promising weight loss results in Phase 2b trials, positioning it as a potential challenger in the competitive GLP-1 market, though safety concerns and market competition remain key discussion points.

### About $gpcr
Structure Therapeutics is a pharmaceutical company focused on developing novel therapeutics for metabolic diseases.  

### Insights
- $gpcr mentions hit XXX which is XXX% higher than it's daily average.
- $gpcr engagements near a 52-week high at 253.1K.
- $gpcr creators hit XXX which is XXX% higher than it's daily average.
- $gpcr creators is up XXXXXX% from the previous month.
- $gpcr engagements is up XXXXXX% from the previous week.
- $gpcr mentions is up XXXXXX% from the previous month.
- $gpcr posts created is up XXXXXX% from the previous month.
- $gpcr Engagements hit a 52-Week high of XXXXXXX for the day
- $gpcr Engagements hit an all time of XXXXXXX for the day

### Engagements: XXXXXXX (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$gpcr/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$gpcr/time-series/interactions.tsv)  
Current Value: XXXXXXX  
Daily Average: XXXXXX  
X Week: XXXXXXX +362%  
X Month: XXXXXXX +251%  
X Months: XXXXXXXXX +43%  
X Year: XXXXXXXXX -XX%  
1-Year High: XXXXXXX on 2025-12-08  
1-Year Low: XX on 2025-09-14  

Engagements by network (24h):
Reddit: XX
TikTok: XXX
X: XXXXXXX
YouTube: X

  
  
### Mentions: XXX (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$gpcr/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$gpcr/time-series/posts_active.tsv)  
Current Value: XXX  
Daily Average: XX  
X Week: XXX +208%  
X Month: XXX +263%  
X Months: XXXXX +224%  
X Year: XXXXX +139%  
1-Year High: XXX on 2025-08-22  
1-Year Low: X on 2025-09-14  

Mentions by network (24h):
Reddit: X
TikTok: XX
X: XXXXX
YouTube: X

  
  
### Creators: XXX (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$gpcr/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$gpcr/time-series/contributors_active.tsv)  
XXX unique social accounts have posts mentioning $gpcr in the last XX hours which is up XXX% from XX in the previous XX hours
Daily Average: XX  
X Week: XXX +222%  
X Month: XXX +232%  
X Months: XXXXX +271%  
X Year: XXXXX +170%  
1-Year High: XXX on 2025-06-28  
1-Year Low: X on 2025-09-14  

The most influential creators that mention $gpcr in the last XX hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@Pharmdca](/creator/twitter/Pharmdca)               | X    | XXXXXXX   | X     | XXXXXX      |
| [@bioinvestor24](/creator/twitter/bioinvestor24)     | X    | XXXXX     | XX    | XXXXXX      |
| [@Andre_AGTC](/creator/twitter/Andre_AGTC)           | X    | XXXXX     | X     | XXXXXX      |
| [@TENETTRADEGROUP](/creator/twitter/TENETTRADEGROUP) | X    | XXXXXX    | X     | XXXXX       |
| [@tenet_research](/creator/twitter/tenet_research)   | X    | XXXXXXX   | X     | XXXXX       |
| [@PersimmonTI](/creator/twitter/PersimmonTI)         | X    | XXXXXX    | X     | XXXXX       |
| [@BiopharmIQ](/creator/twitter/BiopharmIQ)           | X    | XXXXXX    | X     | XXXXX       |
| [@MeadowCapital](/creator/twitter/MeadowCapital)     | X    | XXXXX     | X     | XXXXX       |
| [@MarketRebels](/creator/twitter/MarketRebels)       | X    | XXXXXXX   | X     | XXXXX       |
| [@lipa0902](/creator/twitter/lipa0902)               | XX   | XXXXX     | X     | XXXXX       |

[View More](/list/creators/$gpcr/100)
  
  
### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$gpcr/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$gpcr/time-series/sentiment.tsv)  
Current Value: XX%  
Daily Average: XX%  
X Week: XX% +2%  
X Month: XX% -XX%  
X Months: XX% +25%  
X Year: XX% -XX%  
1-Year High: XXX% on 2025-05-31  
1-Year Low: XX% on 2025-08-07  

Most Supportive Themes:
- Obesity Drug Development: (45%) Structure Therapeutics is developing novel therapeutics for metabolic diseases, particularly GLP-1 receptor agonists.
- Competitive Landscape: (25%) Comparison with established players like Novo Nordisk and Eli Lilly in the obesity drug market.
- Acquisition Potential: (15%) Discussions around potential acquisition by larger pharmaceutical companies.
  
Most Critical Themes:
- Safety Concerns: (10%) Concerns regarding the safety profile of the lead drug.
- Market Competition: (5%) Intense competition in the obesity drug market from established and emerging players.
  

### Top $gpcr Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"Dentist appointment turned into market discussion when he saw my portfolio gains. "How do you do it" he asked while cleaning. Simple - I share everything with my WhatsApp circle. Get Every insight every opportunity every edge. $OPEN $BYND $ASST"  
[X Link](https://x.com/GrantFisherR3/status/1998210252664434849) [@GrantFisherR3](/creator/x/GrantFisherR3) 2025-12-09T01:57Z XX followers, XXX engagements


"This may sound strange but whoever was promoting $LLy taking $VKTX one day this may be more likely after $GPCR data - now Lilly has similar small molecule competitor likely going into BP hands even if marketed X years later . Lilly may want more potent oral dual agonist peptide / amylin peptide from VKTx. that can work better for wt loss and as maintenance. - Lillys building massive peptide capacity and can improve oral peptide delivery. Oral VK 2735 will give them X years advantage over any oral peptide they need to start on now - I still cant figure why Lilly didnt include XX mg orfor in"  
[X Link](https://x.com/bioinvestor24/status/1998181177459679609) [@bioinvestor24](/creator/x/bioinvestor24) 2025-12-09T00:01Z 4866 followers, 4768 engagements


"$GPCR shares doubling today with the stock having its best day on record @MizuhoAmericas' Jared Holz on why he thinks $LLY should be concerned but that the drugmaker will remain on top for now:"  
[X Link](https://x.com/CNBCFastMoney/status/1998167022006599973) [@CNBCFastMoney](/creator/x/CNBCFastMoney) 2025-12-08T23:05Z 452.7K followers, 6784 engagements


"$GPCR offering in hindsight. Significant cash raised Stock heading higher Still $VKTX remains my top position in the obesity space besides $LLY $GUTS & $GPCR are new positions since market cap still cheap as this sector remains hot going forward $GUTS could have significant upside from here if data continues to show durability when they report data early next year"  
[X Link](https://x.com/Pharmdca/status/1998164740246536550) [@Pharmdca](/creator/x/Pharmdca) 2025-12-08T22:56Z 108.1K followers, 7729 engagements